SEC Comment Letter for Applied Therapeutics, Inc. (APLT) (CIK 0001697532) — Jan 17, 2020

Applied Therapeutics, Inc. (APLT) (CIK 0001697532)
Date: Jan. 17, 2020 · CIK: 0001697532 · Accession: 0000000000-20-000456

View on Edgar

AI Filing Summary & Sentiment

Date

January 17, 2020

Author

Not clearly detected

Form

UPLOAD

Company

Applied Therapeutics, Inc. (APLT) (CIK 0001697532)

Letter

January 17, 2020 Shoshana Shendelman, Ph.D. President and Chief Executive Officer Applied Therapeutics Inc. 545 5th Avenue, Suite 1400 New York, NY 10017 Re:Applied Therapeutics Inc. Draft Registration Statement on Form S-1 Submitted Janurary 10, 2020 CIK No. 0001697532 Dear Dr. Shendelman: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement no later than 48 hours prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jeffrey Gabor at 202-551-2544 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Michael J. Schwartz, Esq.

Show Raw Text

January 17, 2020
Shoshana Shendelman, Ph.D.
President and Chief Executive Officer
Applied Therapeutics Inc.
545 5th Avenue, Suite 1400
New York, NY 10017
Re:Applied Therapeutics Inc.
Draft Registration Statement on Form S-1
Submitted Janurary 10, 2020
CIK No. 0001697532
Dear Dr. Shendelman:
            This is to advise you that we do not intend to review your registration statement.
            We request that you publicly file your registration statement no later than 48 hours prior
to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you that the company and its management are responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or
absence of action by the staff.
            Please contact Jeffrey Gabor at 202-551-2544 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Michael J. Schwartz, Esq.

SecProbe.io